Bioventus (BVS) Net Equity Issued and Repurchased (2021 - 2026)

Bioventus' Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at $120000.0 for Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 20.0% year-over-year to $120000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 15.36% YoY) and the FY2025 annual result came in at $2.1 million, down 15.07% from the prior year.
• Net Equity Issued and Repurchased was $120000.0 for Q1 2026 at Bioventus, down from $511000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $2.2 million in Q3 2022 and bottomed at $84000.0 in Q2 2023.
• A 5-year average of $660941.2 and a median of $482000.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased soared 12900.0% — and 2023, when it slumped 95.96%.
• Bioventus' Net Equity Issued and Repurchased stood at $1.1 million in 2022, then sank by 85.41% to $158000.0 in 2023, then surged by 598.1% to $1.1 million in 2024, then sank by 53.67% to $511000.0 in 2025, then tumbled by 76.52% to $120000.0 in 2026.
• Business Quant data shows BVS's Net Equity Issued and Repurchased at $120000.0 in Q1 2026, $511000.0 in Q4 2025, and $96000.0 in Q3 2025.